Loughlin AM, et al. - Researchers performed a propensity-matched cohort study comparing injectable-naive patients with type 2 diabetes initiating exenatide once weekly (EQW) or basal insulin (BI), from 2012 through 2015, within a U.S. electronic health record database. Both glycemic control and weight loss were noted in 25.9% and 14.3% among EQW and BI cohorts, respectively. The incidence of hypoglycemia per 1,000 person-years was 52.5 and 65.7 in the EQW and BI cohorts, respectively. Among EQW, the incidence of nausea was greater relative to BI initiators. Findings suggest that EQW confers an advantage compared to BI in achieving glycemic control and weight loss and a lower incidence of hypoglycemia but with a greater risk for gastrointestinal symptoms.